A detailed history of Dimensional Fund Advisors LP transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 175,744 shares of LRMR stock, worth $1.44 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
175,744
Previous 195,188 9.96%
Holding current value
$1.44 Million
Previous $888,000 50.11%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$4.2 - $13.28 $81,664 - $258,216
-19,444 Reduced 9.96%
175,744 $1.33 Million
Q4 2023

Feb 07, 2024

SELL
$2.35 - $4.71 $68,239 - $136,768
-29,038 Reduced 12.95%
195,188 $888,000
Q3 2023

Nov 09, 2023

SELL
$3.08 - $4.49 $291,623 - $425,126
-94,683 Reduced 29.69%
224,226 $885,000
Q2 2023

Aug 09, 2023

BUY
$3.13 - $5.27 $480,351 - $808,771
153,467 Added 92.76%
318,909 $998,000
Q1 2023

May 12, 2023

BUY
$4.0 - $6.68 $405,100 - $676,517
101,275 Added 157.83%
165,442 $749,000
Q4 2022

Feb 09, 2023

BUY
$2.73 - $5.08 $95,427 - $177,571
34,955 Added 119.66%
64,167 $265,000
Q3 2022

Nov 10, 2022

BUY
$1.53 - $3.64 $6,845 - $16,285
4,474 Added 18.09%
29,212 $93,000
Q2 2022

Aug 12, 2022

SELL
$1.9 - $3.98 $6,460 - $13,532
-3,400 Reduced 12.08%
24,738 $48,000
Q4 2021

Feb 09, 2022

BUY
$8.86 - $13.47 $112,796 - $171,486
12,731 Added 82.63%
28,138 $304,000
Q3 2021

Nov 12, 2021

BUY
$9.61 - $15.11 $148,061 - $232,799
15,407 New
15,407 $178,000
Q2 2021

Aug 12, 2021

SELL
$8.0 - $15.2 $110,736 - $210,398
-13,842 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$14.61 - $22.19 $202,231 - $307,153
13,842 New
13,842 $202,000

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $354M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.